Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...

Internal tandem duplication (ITD) mutation in Fms-like tyrosine ... inhibitors or in combination with FLT3 inhibitors. The details of compounds used for cytotoxicity assay and antibodies used ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and ...

Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but missing out on overall survival.

Researchers at McMaster University have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite ...

PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with full-dose ...

We have found that inhibition of the BCR–ABL tyrosine kinase, either by mutation ... Immunoblottings were performed using 1 μg/ml 4G10 monoclonal antibody against phosphotyrosine (Upstate ...